BioCentury
ARTICLE | Company News

Kymriah deal to stay despite CMS shift on proposed pilot

July 13, 2018 6:55 PM UTC

Novartis AG (NYSE:NVS; SIX:NOVN) said on July 9 an outcomes-based contract for Kymriah tisagenlecleucel remains in effect with treatment centers. The contract is unaffected by CMS's decision not to pursue the pharma's proposal for a demonstration program including indication-based pricing.

A CMS spokesperson told BioCentury the agency "reviewed Novartis’s proposed demonstration and then decided to go in a different direction," but declined to provide details...

BCIQ Company Profiles

Novartis AG